Taysha Gene Therapies (NASDAQ:TSHA) Rating Reiterated by Cantor Fitzgerald
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a note issued to investors on Thursday, Benzinga reports. They currently have a $7.00 target price on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 136.49% from the company’s previous […]
More Stories
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...
DoubleLine Income Solutions Fund (NYSE:DSL) Shares Pass Below 200-Day Moving Average – Should You Sell?
Shares of DoubleLine Income Solutions Fund (NYSE:DSL – Get Free Report) passed below its 200-day moving average during trading on...
DoubleLine Income Solutions Fund (NYSE:DSL) Shares Pass Below 200-Day Moving Average – Should You Sell?
Shares of DoubleLine Income Solutions Fund (NYSE:DSL – Get Free Report) passed below its 200-day moving average during trading on...
DoubleLine Income Solutions Fund (NYSE:DSL) Shares Pass Below 200-Day Moving Average – Should You Sell?
Shares of DoubleLine Income Solutions Fund (NYSE:DSL – Get Free Report) passed below its 200-day moving average during trading on...